Summary: On March 7, 2011, the U.S. Supreme Court denied a petition for a writ of certiorari filed by various drug purchasers in which they asked the Court to review so-called reverse payments, an arrangement that settles patent litigation brought by brand-name drug manufacturers against generic manufacturers. Under a so-called reverse payment arrangement, the brand-name manufacturer makes a payment to the generic manufacturer in consideration for the generic manufacturer’s agreement not to produce the challenged product.
The Court’s denial let stand a Second Circuit decision that rejected antitrust claims based on a settlement between Bayer AG, the owner of a patent for ciprofloxacin (“Cipro”), and Barr Laboratories, Inc., a generic manufacturer that had challenged the patent. The attached Client Alert provides the background leading up to, and the significance of, the Supreme Court’s denial.
Also of Interest
- Bloomberg Business: Moriarty Returns for “Taking Stock” ETFs & Bitcoin Podcast September 22, 2016 • Media Mentions
- O’Keefe Featured in the Daily Journal on the 2016 Proxy Season September 15, 2016 • Media Mentions
- Pro Bono Team Advances CodeEd’s Comp Sci Efforts for Coeds September 14, 2016 • Client Successes
- SEC Proposes Exhibit Hyperlink Requirements September 8, 2016 • Client Alerts
- Arbisser Featured in The Recorder and Law360... September 7, 2016 • Media Mentions
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- ILS and Zinsser Analytic Shareholders Sell to Gardner Denver Medical September 2, 2016 • Client Successes
- Kaye Scholer Secures Dismissal of Merger-Related Class Action Against Baltic Trading September 1, 2016 • Client Successes
- Kaye Scholer Advises Veracen on Merger of Equals with Turner Investments August 31, 2016 • Client Successes